Bullet Bio develops next-generation combination immunotherapies with curative potential, including therapeutic vaccines and multi-specific antibodies.
Bullet Bio is developing active immunotherapies that train your immune system to fight disease. Our lead product is a personalized immunotherapy that targets a tumor-specific antigen present on B-cell lymphoma cells. We are pursuing a minimal infrastructure, "virtual" model, focusing on developing products and generating intellectual property. We plan to file our first IND application (the document that enables clinical trials) in 4Q15.